BTG INT LTD has a total of 1,385 patent applications. It increased the IP activity by 1400.0%. Its first patent ever was published in 1985. It filed its patents most often in United States, EPO (European Patent Office) and United Kingdom. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are NOVARTIS AG *, ORION YHTYMAE OYJ and ALLERGAN INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 293 | |
#2 | EPO (European Patent Office) | 266 | |
#3 | United Kingdom | 147 | |
#4 | WIPO (World Intellectual Property Organization) | 147 | |
#5 | Canada | 122 | |
#6 | Australia | 121 | |
#7 | China | 43 | |
#8 | Republic of Korea | 36 | |
#9 | Hong Kong | 32 | |
#10 | South Africa | 25 | |
#11 | Brazil | 23 | |
#12 | Mexico | 18 | |
#13 | New Zealand | 18 | |
#14 | Israel | 17 | |
#15 | Norway | 10 | |
#16 | Taiwan | 7 | |
#17 | Hungary | 6 | |
#18 | Japan | 5 | |
#19 | Czechia | 4 | |
#20 | Finland | 4 | |
#21 | Poland | 4 | |
#22 | Argentina | 3 | |
#23 | India | 3 | |
#24 | Switzerland | 2 | |
#25 | Germany | 2 | |
#26 | Spain | 2 | |
#27 | Iceland | 2 | |
#28 | Luxembourg | 2 | |
#29 | Morocco | 2 | |
#30 | Netherlands | 2 | |
#31 | Singapore | 2 | |
#32 | African Regional Industrial Property Organization | 1 | |
#33 | Bulgaria | 1 | |
#34 | Denmark | 1 | |
#35 | EAPO (Eurasian Patent Organization) | 1 | |
#36 | Ecuador | 1 | |
#37 | Estonia | 1 | |
#38 | Egypt | 1 | |
#39 | Malaysia | 1 | |
#40 | African Intellectual Property Organization | 1 | |
#41 | Peru | 1 | |
#42 | Serbia | 1 | |
#43 | Saudi Arabia | 1 | |
#44 | Sweden | 1 | |
#45 | Slovenia | 1 | |
#46 | Yugoslavia (Serbia and Montenegro) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Medical technology | |
#5 | Machines | |
#6 | Measurement |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Unspecified technologies | |
#4 | Heterocyclic compounds | |
#5 | Syringes | |
#6 | Peptides | |
#7 | Microorganisms | |
#8 | Diagnosis and surgery | |
#9 | Acyclic or carbocyclic compounds | |
#10 | Measuring electric variables |
# | Name | Total Patents |
---|---|---|
#1 | Harman Anthony David | 113 |
#2 | Wright David Dakin Iorwerth | 83 |
#3 | Robinson Nikki | 47 |
#4 | Hodges Garry | 45 |
#5 | Harbige Laurence S | 41 |
#6 | Moggridge Geoffrey D | 40 |
#7 | Leach Michael J | 40 |
#8 | Kadar Adil | 39 |
#9 | Osman Tariq | 39 |
#10 | Ward Ian Macmillan | 35 |
Publication | Filing date | Title |
---|---|---|
US2020197402A1 | Platinum-resistant cancer treatment | |
CA3062552A1 | Platinum-resistant cancer treatment | |
US2016279233A1 | Epitopes related to coeliac disease | |
JP2012246306A | Injectable foam preparation, and new pharmaceutical application | |
AU2011247868A1 | Epitopes related to coeliac disease | |
AU2010295311A1 | Reconstitutable reverse thermal gelling polymers | |
GB0919950D0 | Clamp and applicator | |
GB0917775D0 | Novel pharmaceutical compounds | |
US2009253781A1 | Therapeutic compositions | |
CA2717954A1 | Cyclopenta[g]quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia | |
GB0901836D0 | EP4 receptor antagonists | |
GB0900756D0 | EP4 Receptor antagonists | |
GB0900755D0 | Ep4 receptor antagonists | |
GB0900754D0 | EP4 Receptor antagonists | |
GB0820268D0 | Novel synthetic method | |
GB0820263D0 | Snythrtic method | |
GB0805036D0 | New use of cyclopenta[g]quinazoline derivatives | |
GB0805035D0 | Us eof cyclopenta[G]quinazoline derivatives | |
GB0803019D0 | Fluorinated compounds | |
CN102950695A | Device and method for producing therapeutic foam |